MIRA's Oral SKNY-1 Cuts Weight and Fat in Obese Mice, With Less Lean-Mass Loss Than Semaglutide
MIRA is trading near its 52-week low of $0.518 (7.3% above the low) on light trading volume (0.1× avg).
Summary
MIRA reported positive pilot data for oral SKNY-1 in obese mice, including significant weight and fat loss with no significant lean-mass loss and limited weight regain after treatment stopped, contrasting with semaglutide. The results are preclinical only and do not address the company's going-concern and Nasdaq listing issues.
Key Events · Product Development and Regulatory · MIRA
-
SKNY-1 Pilot Hits Weight and Fat Endpoints
In a diet-induced obese mouse model, oral SKNY-1 produced statistically significant reductions in body weight and fat mass versus vehicle-treated controls, with most of the weight difference attributable to fat reduction.
-
Differentiation Claims Versus Semaglutide
SKNY-1-treated mice showed no statistically significant lean-mass loss versus vehicle while semaglutide mice did, and regained weight slowly over a two-week post-treatment period versus rapid rebound on semaglutide.
-
Possible Non-Appetite Mechanism
Weight loss occurred without a statistically significant decrease in food consumption, which MIRA says raises the possibility SKNY-1 acts on energy expenditure or other metabolic pathways rather than appetite suppression.
-
Preclinical Only, Next Study Planned
The data come from an exploratory pilot in mice; MIRA said its next study will directly measure energy expenditure and other metabolic parameters while it runs longer-term preclinical work and IND-enabling CMC manufacturing.
Analysis · MIRA · Life Sciences
MIRA posted initial proof-of-concept data for SKNY-1, its oral obesity candidate, in a diet-induced obese mouse model. What moves the stock is the differentiation versus semaglutide: weight and fat fell significantly without a significant drop in food intake, treated mice kept lean mass while semaglutide mice lost it, and weight regain after stopping was slow versus a rapid rebound on semaglutide. That points to an energy-expenditure mechanism rather than appetite suppression, which is the story management is selling. The caveats are large: this is an exploratory pilot in mice, not a human trial, and the company has no clinical obesity data. Against a going-concern warning and a Nasdaq bid-price deficiency previously disclosed, positive preclinical readouts are the main lever MIRA has to support sentiment and future financing, but they do not change the cash runway into Q1 2027.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRA was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.4M. The 52-week trading range was $0.52 to $1.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.